HIV Drug Resistance Early Warning Indicators in Cohorts of Individuals Starting Antiretroviral Therapy Between 2004 and 2009: World Health Organization Global Report From 50 Countries
Open Access
- 15 May 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 54 (suppl_4), S280-S289
- https://doi.org/10.1093/cid/cis207
Abstract
The World Health Organization developed a set of human immunodeficiency virus drug resistance (HIVDR) early warning indicators (EWIs) to assess antiretroviral therapy clinic and program factors associated with HIVDR. EWIs are monitored by abstracting data routinely recorded in clinical records, and the results enable clinics and program managers to identify problems that should be addressed to minimize preventable emergence of HIVDR in clinic populations. As of June 2011, 50 countries monitored EWIs, covering 131 686 patients initiating antiretroviral treatment between 2004 and 2009 at 2107 clinics. HIVDR prevention is associated with patient care (appropriate prescribing and patient monitoring), patient behavior (adherence), and clinic/program management efforts to reduce treatment interruptions (follow up, retention on first-line ART, procurement and supply management of antiretroviral drugs). EWIs measure these factors and the results have been used to optimize patient and population treatment outcomes.This publication has 43 references indexed in Scilit:
- Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1–Infected Adults on Antiretroviral Therapy in Côte d'IvoireJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Pharmacy Adherence Measures to Assess Adherence to Antiretroviral Therapy: Review of the Literature and Implications for Treatment MonitoringClinical Infectious Diseases, 2011
- Measuring adherence to antiretroviral treatment in resource-poor settings: The feasibility of collecting routine data for key indicatorsBMC Health Services Research, 2010
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentAIDS, 2009
- Response to Zidovudine/Didanosine-Containing Combination Antiretroviral Therapy Among HIV-1 Subtype C-Infected Adults in Botswana: Two-Year Outcomes from a Randomized Clinical TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Transportation Costs Impede Sustained Adherence and Access to HAART in a Clinic Population in Southwestern Uganda: A Qualitative StudyAIDS and Behavior, 2009
- Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence LevelsPLOS ONE, 2008
- Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral TherapyPLoS Medicine, 2008
- Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and FacilitatorsPLoS Medicine, 2006
- The Price of Adherence: Qualitative Findings From HIV Positive Individuals Purchasing Fixed-Dose Combination Generic HIV Antiretroviral Therapy in Kampala, UgandaAIDS and Behavior, 2006